August 5 Deadlines for Small Business Cancer Technology Grant Funding Opportunities

Apply Today!

August 5 Deadlines for Small Business Cancer Technology Grant Funding Opportunities

The National Cancer Institute Small Business Innovation Research and Small Business Technology Transfer (NCI SBIR & STTR) Programs are designed to catalyze the development of innovative technologies and therapeutics to further cancer research, prevention, detection, and treatment. Funding from the NCI can help you advance your technology towards commercialization and can also help spark investor interest in your business.

We encourage you to review the opportunities below and consider applying for funding. NCI SBIR Development Center Program Directors are available to discuss ideas and opportunities with you.

2014 SBIR and STTR Omnibus Solicitation

The 2014 SBIR and STTR Omnibus Solicitation is an investigator-initiated grant funding opportunity that supports small businesses proposing innovative cancer-related technologies, with strong commercial potential, across a wide range of cancer-related research topic areas.

If you would like to take advantage of this opportunity, please review the topics of interest for the NCI and email the NCI SBIR Program Director listed in your relevant technology area.

PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Receipt Dates: August 5, 2014; December 5, 2014

PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Receipt Dates: August 5, 2014; December 5, 2014
Direct-to-Phase II Pilot Program

The NCI SBIR Development Center implemented the SBIR Direct-to-Phase II Pilot solicitation, per the 2011 SBIR & STTR Reauthorization Act, to allow applicants that have demonstrated the R&D and technical merit characteristic of a Phase I (R43) SBIR project to bypass Phase I and apply directly for SBIR Phase II grants. This program applies to SBIR only, NOT STTR.

The Direct-to-Phase II pilot program is designed to expand opportunities for small business concerns and accelerate the pace of technology development and commercialization.

PAR-14-088. Direct Phase II SBIR Grants to Support Biomedical Technology Development
Receipt dates: August 5, 2014; December 5, 2014
Additional grant funding opportunities include:

PA-12-196, Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR) (R44)
Receipt dates: August 5, 2014; December 5, 2014

PA-13-140 Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44)
Receipt dates: August 5, 2014; December 5, 2014; April 5, 2015; August 5, 2015; December 5, 2015

Who is Eligible to Apply:
U.S. small business concerns

  • SBIR & STTR: Small business concerns that are more than 50% directly owned and controlled by one or more individuals, other business concerns, or any combination of these; OR be a joint venture in which each entity in the joint venture must meet certain requirements.
  • SBIR only: Small business concerns that are more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these.

Tips for Applying:

Questions?
Contact the NCI SBIR Development Center at NCIsbir@mail.nih.gov, or a Program Director with the relevant area of expertise.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: